Zymo Analysis Company (Zymo Analysis), a pacesetter in revolutionary life science options, introduced right this moment that it has filed claims within the United District Courtroom for the Central District of California in opposition to Qiagen GmbH (Qiagen) alleging that Qiagen has engaged in antitrust violations and improperly interfered with Zymo Analysis’s contractual relations. These claims had been filed as a part of an amended response to a patent infringement lawsuit beforehand filed by Qiagen. Along with asserting its claims for antitrust and interference, Zymo Analysis’s amended response denies all of Qiagen’s allegations of infringement.
Zymo Analysis believes that Qiagen’s lawsuit is a component of a bigger technique to misuse litigation as a instrument to stifle innovation and delay the adoption of groundbreaking applied sciences that profit the scientific and medical communities. By bringing its counterclaims, Zymo Analysis not solely intends to vindicate its place within the lawsuit in opposition to Qiagen, however to make clear the misuse of litigation as a weapon in opposition to technological progress.
“Qiagen’s lawsuit was not introduced in good religion and lacks benefit. The scientific neighborhood deserves entry to cutting-edge instruments that foster progress and discovery, and we’re dedicated to defending our breakthrough cfDNA expertise and our contributions to the scientific neighborhood.” stated Dr. Marc Van Eden, VP of Company Growth.
:quality(85):upscale()/2024/10/31/696/n/1922564/89d61aee6723a5abe1f237.23197889_.png?w=75&resize=75,75&ssl=1)
